2FV Stock Overview
ScandiDos AB (publ) engages in the provision of measurement systems and software designed for the QA and validation of new dynamic and modulated treatments implemented in clinics worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ScandiDos AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.12 |
| 52 Week High | kr0.21 |
| 52 Week Low | kr0.11 |
| Beta | 1.14 |
| 1 Month Change | 3.00% |
| 3 Month Change | -25.70% |
| 1 Year Change | -23.08% |
| 3 Year Change | -71.01% |
| 5 Year Change | -53.31% |
| Change since IPO | -76.38% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2FV | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -6.3% | 2.1% | 0.5% |
| 1Y | -23.1% | -8.4% | 1.3% |
Price Volatility
| 2FV volatility | |
|---|---|
| 2FV Average Weekly Movement | 13.9% |
| Medical Equipment Industry Average Movement | 4.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2FV's share price has been volatile over the past 3 months.
Volatility Over Time: 2FV's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 30 | Carl Piehl | scandidos.com |
ScandiDos AB (publ) engages in the provision of measurement systems and software designed for the QA and validation of new dynamic and modulated treatments implemented in clinics worldwide. It offers Delta4 Discover and Delta4 Phantom+ for the QA of advanced radiation therapy procedures such as VMAT, RapidArc, IMRT, and Tomotherapy. The company was incorporated in 2001 and is headquartered in Uppsala, Sweden.
ScandiDos AB (publ) Fundamentals Summary
| 2FV fundamental statistics | |
|---|---|
| Market cap | €6.68m |
| Earnings (TTM) | -€415.36k |
| Revenue (TTM) | €5.81m |
1.1x
P/S Ratio-16.1x
P/E RatioIs 2FV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2FV income statement (TTM) | |
|---|---|
| Revenue | kr67.88m |
| Cost of Revenue | kr14.17m |
| Gross Profit | kr53.71m |
| Other Expenses | kr58.57m |
| Earnings | -kr4.85m |
Last Reported Earnings
Jan 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.11 |
| Gross Margin | 79.13% |
| Net Profit Margin | -7.15% |
| Debt/Equity Ratio | 0% |
How did 2FV perform over the long term?
See historical performance and comparison